Generic Association’s New CEO Signals Focus On Communications
Dan Leonard Replaces Chip Davis At US AAM
Dan Leonard’s communications background, in addition to his policy expertise, may prove useful for the Association for Accessible Medicines as it navigates ongoing market and public policy challenges.
You may also be interested in...
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
The FDA has called on public stakeholders to notify the agency of their participation in the next Generic Drug User Fee Amendments program, as it sets the agenda for improving the generic drug approval process, including for complex generics.
The AAM’s new CEO, Dan Leonard, has set out his priorities for the industry association, highlighting current industry challenges as well as throwing light on how generics can be the “bridge” to a COVID-19 vaccine.